Intralesional human papillomavirus vaccine for the treatment of recalcitrant cutaneous warts
The Journal of Dermatology · 2023
DOI: 10.1111/1346-8138.16905 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Dermatology, 2023. Verfasst von Efrat Bar-Ilan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. Hauptthemen laut MEDLINE: Warts, Papillomavirus Vaccines, Papillomavirus Infections. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Human papillomavirus (HPV) is ubiquitously distributed in the population worldwide and its most frequent clinical presentation is cutaneous warts. Despite various treatment options currently available, many patients experience persistent and refractory disease. We sought to evaluate the clinical effectiveness and safety profile of intralesional HPV 9‐valent vaccine for the treatment of recalcitrant warts. A retrospective study was performed for all cases of cutaneous warts treated with intralesional 9‐valent HPV vaccine between January 2017 and March 2021. Epidemiologic, clinical, and treatment data, including safety and effectiveness scores, were reviewed. Our cohort was composed of 20 patients: 13 adults and seven children. Twelve patients (60%) displayed a complete response whereas 8 patients (40%) showed a partial response. Older age was associated with a better response to treatment, while a history of laser therapy was associated with a worse prognosis. Adverse events were local, transient, and negligible. No systemic adverse effects were reported. Intralesional 9‐valent HPV vaccine may be considered for the treatment of recalcitrant cutaneous warts. Controlled studies are required to confirm these results.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
- Pediatric Dermatology Clinic, Sourasky Medical Center, Dana-Dwek Children's Hospital, Tel Aviv, Israel.
ORCID-Profile: Ofir Artzi
Zitieren
APA
Bar-Ilan, E., Bar, J., Baniel, A., Slodownik, D., Artzi, O., Samuelov, L., Sprecher, E., & Mashiah, J. (2023). Intralesional human papillomavirus vaccine for the treatment of recalcitrant cutaneous warts. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.16905
Vancouver
Bar-Ilan E, Bar J, Baniel A, Slodownik D, Artzi O, Samuelov L, et al. Intralesional human papillomavirus vaccine for the treatment of recalcitrant cutaneous warts. The Journal of Dermatology. 2023. doi:10.1111/1346-8138.16905
BibTeX
@article{BarIlan2023,
author = {Bar-Ilan, Efrat and Bar, Jonathan and Baniel, Avital and Slodownik, Dan and Artzi, Ofir and Samuelov, Liat and Sprecher, Eli and Mashiah, Jacob},
title = {Intralesional human papillomavirus vaccine for the treatment of recalcitrant cutaneous warts},
journal = {The Journal of Dermatology},
year = {2023},
doi = {10.1111/1346-8138.16905}
}
EUVIMED